1
|
Lang M, Schmidt LS, Wilson KM, Ricketts CJ, Sourbier C, Vocke CD, Wei D, Crooks DR, Yang Y, Gibbs BK, Zhang X, Klumpp-Thomas C, Chen L, Guha R, Ferrer M, McKnight C, Itkin Z, Wangsa D, Wangsa D, James A, Difilippantonio S, Karim B, Morís F, Ried T, Merino MJ, Srinivasan R, Thomas CJ, Linehan WM. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma. J Exp Clin Cancer Res 2023; 42:99. [PMID: 37095531 PMCID: PMC10127337 DOI: 10.1186/s13046-023-02667-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 04/06/2023] [Indexed: 04/26/2023] Open
Abstract
BACKGROUND MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can present with heterogeneous histological features making diagnosis challenging. Moreover, the disease biology of this aggressive cancer is poorly understood and there is no accepted standard of care therapy for patients with advanced disease. Tumor-derived cell lines have been established from human TFE3-RCC providing useful models for preclinical studies. METHODS TFE3-RCC tumor derived cell lines and their tissues of origin were characterized by IHC and gene expression analyses. An unbiased high-throughput drug screen was performed to identify novel therapeutic agents for treatment of MiT-RCC. Potential therapeutic candidates were validated in in vitro and in vivo preclinical studies. Mechanistic assays were conducted to confirm the on-target effects of drugs. RESULTS The results of a high-throughput small molecule drug screen utilizing three TFE3-RCC tumor-derived cell lines identified five classes of agents with potential pharmacological efficacy, including inhibitors of phosphoinositide-3-kinase (PI3K) and mechanistic target of rapamycin (mTOR), and several additional agents, including the transcription inhibitor Mithramycin A. Upregulation of the cell surface marker GPNMB, a specific MiT transcriptional target, was confirmed in TFE3-RCC and evaluated as a therapeutic target using the GPNMB-targeted antibody-drug conjugate CDX-011. In vitro and in vivo preclinical studies demonstrated efficacy of the PI3K/mTOR inhibitor NVP-BGT226, Mithramycin A, and CDX-011 as potential therapeutic options for treating advanced MiT-RCC as single agents or in combination. CONCLUSIONS The results of the high-throughput drug screen and validation studies in TFE3-RCC tumor-derived cell lines have provided in vitro and in vivo preclinical data supporting the efficacy of the PI3K/mTOR inhibitor NVP-BGT226, the transcription inhibitor Mithramycin A, and GPNMB-targeted antibody-drug conjugate CDX-011 as potential therapeutic options for treating advanced MiT-RCC. The findings presented here should provide the basis for designing future clinical trials for patients with MiT-driven RCC.
Collapse
Affiliation(s)
- Martin Lang
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, 39100, Italy
| | - Laura S Schmidt
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Kelli M Wilson
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Christopher J Ricketts
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Carole Sourbier
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Cathy D Vocke
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Darmood Wei
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Daniel R Crooks
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Youfeng Yang
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Benjamin K Gibbs
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Xiaohu Zhang
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Carleen Klumpp-Thomas
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Lu Chen
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Rajarshi Guha
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Marc Ferrer
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Crystal McKnight
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Zina Itkin
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - Darawalee Wangsa
- Genetics Branch, Cancer Genomics Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Danny Wangsa
- Genetics Branch, Cancer Genomics Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Amy James
- Laboratory of Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Simone Difilippantonio
- Laboratory of Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Baktir Karim
- Laboratory of Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, Calle Colegio Santo Domingo Guzmán, Oviedo, AS, 33011, Spain
| | - Thomas Ried
- Genetics Branch, Cancer Genomics Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Maria J Merino
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ramaprasad Srinivasan
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Craig J Thomas
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
| | - W Marston Linehan
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
| |
Collapse
|
2
|
Lopez-Millan B, Costales P, Gutiérrez-Agüera F, Díaz de la Guardia R, Roca-Ho H, Vinyoles M, Rubio-Gayarre A, Safi R, Castaño J, Romecín PA, Ramírez-Orellana M, Anguita E, Jeremias I, Zamora L, Rodríguez-Manzaneque JC, Bueno C, Morís F, Menendez P. The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. Cancers (Basel) 2022; 14:cancers14061593. [PMID: 35326743 PMCID: PMC8946166 DOI: 10.3390/cancers14061593] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 03/11/2022] [Indexed: 12/17/2022] Open
Abstract
Simple Summary Patients with AML harboring constitutively active mutations in the FLT3 receptor generally have a poor prognosis (FLT3-ITDMUT). Despite the fact that several FLT3 inhibitors have been developed, clinical responses are commonly partial or not durable, highlighting the need for new molecules targeting FLT3-ITDMUT. Here, we tested EC-70124, a hybrid indolocarbazole analog from the same chemical space as midostaurin (a well-known FLT3 inhibitor). Our in vitro and in vivo experiments showed that EC-70124 exerts a robust and specific antileukemia activity against FLT3-ITDMUT AML cells while sparing healthy hematopoietic cells. Collectively, EC-70124 is a promising and safe agent for the treatment of this aggressive type of AML. Abstract Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Patients with AML harboring a constitutively active internal tandem duplication mutation (ITDMUT) in the FMS-like kinase tyrosine kinase (FLT3) receptor generally have a poor prognosis. Several tyrosine kinase/FLT3 inhibitors have been developed and tested clinically, but very few (midostaurin and gilteritinib) have thus far been FDA/EMA-approved for patients with newly diagnosed or relapse/refractory FLT3-ITDMUT AML. Disappointingly, clinical responses are commonly partial or not durable, highlighting the need for new molecules targeting FLT3-ITDMUT AML. Here, we tested EC-70124, a hybrid indolocarbazole analog from the same chemical space as midostaurin with a potent and selective inhibitory effect on FLT3. In vitro, EC-70124 exerted a robust and specific antileukemia activity against FLT3-ITDMUT AML primary cells and cell lines with respect to cytotoxicity, CFU capacity, apoptosis and cell cycle while sparing healthy hematopoietic (stem/progenitor) cells. We also analyzed its efficacy in vivo as monotherapy using two different xenograft models: an aggressive and systemic model based on MOLM-13 cells and a patient-derived xenograft model. Orally disposable EC-70124 exerted a potent inhibitory effect on the growth of FLT3-ITDMUT AML cells, delaying disease progression and debulking the leukemia. Collectively, our findings show that EC-70124 is a promising and safe agent for the treatment of AML with FLT3-ITDMUT.
Collapse
Affiliation(s)
- Belen Lopez-Millan
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain;
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Correspondence: (B.L.-M.); (P.M.)
| | | | - Francisco Gutiérrez-Agüera
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
| | - Rafael Díaz de la Guardia
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain;
| | - Heleia Roca-Ho
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
| | - Meritxell Vinyoles
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
| | - Alba Rubio-Gayarre
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain;
| | - Rémi Safi
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
| | - Julio Castaño
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
| | - Paola Alejandra Romecín
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
| | - Manuel Ramírez-Orellana
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación Sanitaria La Princesa, 28006 Madrid, Spain
| | - Eduardo Anguita
- Servicio de Hematología, Hospital Clínico San Carlos, IdISSC, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain;
| | - Irmela Jeremias
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, 85764 Munich, Germany;
| | - Lurdes Zamora
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- Hematology Department, ICO-Hospital Germans Trias i Pujol, 08916 Barcelona, Spain
| | | | - Clara Bueno
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Centro de Investigación Biomédica en Red–Oncología (CIBERONC), 28029 Madrid, Spain
| | | | - Pablo Menendez
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (F.G.-A.); (R.D.d.l.G.); (H.R.-H.); (M.V.); (A.R.-G.); (R.S.); (J.C.); (P.A.R.); (L.Z.); (C.B.)
- Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Centro de Investigación Biomédica en Red–Oncología (CIBERONC), 28029 Madrid, Spain
- Instituciò Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
- Correspondence: (B.L.-M.); (P.M.)
| |
Collapse
|
3
|
Botas A, Eitel M, Schwarz PN, Buchmann A, Costales P, Núñez LE, Cortés J, Morís F, Krawiec M, Wolański M, Gust B, Rodriguez M, Fischer W, Jandeleit B, Zakrzewska‐Czerwińska J, Wohlleben W, Stegmann E, Koch P, Méndez C, Gross H. Genetic Engineering in Combination with Semi‐Synthesis Leads to a New Route for Gram‐Scale Production of the Immunosuppressive Natural Product Brasilicardin A. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202015852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Alma Botas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias Universidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA) c/ Julián Clavería s/n. 33006 Oviedo Spain
| | - Michael Eitel
- Department of Pharmaceutical Chemistry Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Paul N. Schwarz
- Department of Microbiology and Biotechnology Interfaculty Institute of Microbiology and Infection Medicine University of Tübingen Auf der Morgenstelle 28 72076 Tübingen Germany
| | - Anina Buchmann
- Department of Pharmaceutical Biology Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Paula Costales
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Luz Elena Núñez
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Jesús Cortés
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Francisco Morís
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Michał Krawiec
- Department of Molecular Microbiology Faculty of Biotechnology University of Wrocław ul. F. Joliot-Curie 14A 50-383 Wrocław Poland
| | - Marcin Wolański
- Department of Molecular Microbiology Faculty of Biotechnology University of Wrocław ul. F. Joliot-Curie 14A 50-383 Wrocław Poland
| | - Bertolt Gust
- Department of Pharmaceutical Biology Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Mirna Rodriguez
- Quadriga BioSciences, Inc. 339 S. San Antonio Road, Suite 2A Los Altos CA 94022 USA
| | - Wolf‐Nicolas Fischer
- Quadriga BioSciences, Inc. 339 S. San Antonio Road, Suite 2A Los Altos CA 94022 USA
| | - Bernd Jandeleit
- Quadriga BioSciences, Inc. 339 S. San Antonio Road, Suite 2A Los Altos CA 94022 USA
| | - Jolanta Zakrzewska‐Czerwińska
- Department of Molecular Microbiology Faculty of Biotechnology University of Wrocław ul. F. Joliot-Curie 14A 50-383 Wrocław Poland
| | - Wolfgang Wohlleben
- Department of Microbiology and Biotechnology Interfaculty Institute of Microbiology and Infection Medicine University of Tübingen Auf der Morgenstelle 28 72076 Tübingen Germany
| | - Evi Stegmann
- Department of Microbiology and Biotechnology Interfaculty Institute of Microbiology and Infection Medicine University of Tübingen Auf der Morgenstelle 28 72076 Tübingen Germany
| | - Pierre Koch
- Department of Pharmaceutical Chemistry Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias Universidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA) c/ Julián Clavería s/n. 33006 Oviedo Spain
| | - Harald Gross
- Department of Pharmaceutical Biology Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| |
Collapse
|
4
|
Botas A, Eitel M, Schwarz PN, Buchmann A, Costales P, Núñez LE, Cortés J, Morís F, Krawiec M, Wolański M, Gust B, Rodriguez M, Fischer W, Jandeleit B, Zakrzewska‐Czerwińska J, Wohlleben W, Stegmann E, Koch P, Méndez C, Gross H. Genetic Engineering in Combination with Semi-Synthesis Leads to a New Route for Gram-Scale Production of the Immunosuppressive Natural Product Brasilicardin A. Angew Chem Int Ed Engl 2021; 60:13536-13541. [PMID: 33768597 PMCID: PMC8251711 DOI: 10.1002/anie.202015852] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 02/28/2021] [Indexed: 01/01/2023]
Abstract
Brasilicardin A (1) consists of an unusual anti/syn/anti-perhydrophenanthrene skeleton with a carbohydrate side chain and an amino acid moiety. It exhibits potent immunosuppressive activity, yet its mode of action differs from standard drugs that are currently in use. Further pre-clinical evaluation of this promising, biologically active natural product is hampered by restricted access to the ready material, as its synthesis requires both a low-yielding fermentation process using a pathogenic organism and an elaborate, multi-step total synthesis. Our semi-synthetic approach included a) the heterologous expression of the brasilicardin A gene cluster in different non-pathogenic bacterial strains producing brasilicardin A aglycone (5) in excellent yield and b) the chemical transformation of the aglycone 5 into the trifluoroacetic acid salt of brasilicardin A (1 a) via a short and straightforward five-steps synthetic route. Additionally, we report the first preclinical data for brasilicardin A.
Collapse
Affiliation(s)
- Alma Botas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de AsturiasUniversidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA)c/ Julián Clavería s/n.33006OviedoSpain
| | - Michael Eitel
- Department of Pharmaceutical ChemistryInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Paul N. Schwarz
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenAuf der Morgenstelle 2872076TübingenGermany
| | - Anina Buchmann
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Paula Costales
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Luz Elena Núñez
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Jesús Cortés
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Francisco Morís
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Michał Krawiec
- Department of Molecular MicrobiologyFaculty of BiotechnologyUniversity of Wrocławul. F. Joliot-Curie 14A50-383WrocławPoland
| | - Marcin Wolański
- Department of Molecular MicrobiologyFaculty of BiotechnologyUniversity of Wrocławul. F. Joliot-Curie 14A50-383WrocławPoland
| | - Bertolt Gust
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Mirna Rodriguez
- Quadriga BioSciences, Inc.339 S. San Antonio Road, Suite 2ALos AltosCA94022USA
| | | | - Bernd Jandeleit
- Quadriga BioSciences, Inc.339 S. San Antonio Road, Suite 2ALos AltosCA94022USA
| | - Jolanta Zakrzewska‐Czerwińska
- Department of Molecular MicrobiologyFaculty of BiotechnologyUniversity of Wrocławul. F. Joliot-Curie 14A50-383WrocławPoland
| | - Wolfgang Wohlleben
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenAuf der Morgenstelle 2872076TübingenGermany
| | - Evi Stegmann
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenAuf der Morgenstelle 2872076TübingenGermany
| | - Pierre Koch
- Department of Pharmaceutical ChemistryInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de AsturiasUniversidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA)c/ Julián Clavería s/n.33006OviedoSpain
| | - Harald Gross
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| |
Collapse
|
5
|
Telzerow A, Paris J, Håkansson M, González‐Sabín J, Ríos‐Lombardía N, Gröger H, Morís F, Schürmann M, Schwab H, Steiner K. Expanding the Toolbox of R-Selective Amine Transaminases by Identification and Characterization of New Members. Chembiochem 2021; 22:1232-1242. [PMID: 33242357 PMCID: PMC8048526 DOI: 10.1002/cbic.202000692] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 11/22/2020] [Indexed: 12/16/2022]
Abstract
Amine transaminases (ATAs) are used to synthesize enantiomerically pure amines, which are building blocks for pharmaceuticals and agrochemicals. R-selective ATAs belong to the fold type IV PLP-dependent enzymes, and different sequence-, structure- and substrate scope-based features have been identified in the past decade. However, our knowledge is still restricted due to the limited number of characterized (R)-ATAs, with additional bias towards fungal origin. We aimed to expand the toolbox of (R)-ATAs and contribute to the understanding of this enzyme subfamily. We identified and characterized four new (R)-ATAs. The ATA from Exophiala sideris contains a motif characteristic for d-ATAs, which was previously believed to be a disqualifying factor for (R)-ATA activity. The crystal structure of the ATA from Shinella is the first from a Gram-negative bacterium. The ATAs from Pseudonocardia acaciae and Tetrasphaera japonica are the first characterized (R)-ATAs with a shortened/missing N-terminal helix. The active-site charges vary significantly between the new and known ATAs, correlating with their diverging substrate scope.
Collapse
Affiliation(s)
- Aline Telzerow
- Institute of Molecular BiotechnologyGraz University of TechnologyPetersgasse 148010GrazAustria
- InnoSyn B.V.Urmonderbaan 226167RDGeleenThe Netherlands
| | - Juraj Paris
- Chair of Industrial Organic Chemistry and BiotechnologyFaculty of ChemistryBielefeld UniversityUniversitätsstr. 2533615BielefeldGermany
- EntreChem SLVivero Ciencias de la Salud33011OviedoSpain
| | | | | | | | - Harald Gröger
- Chair of Industrial Organic Chemistry and BiotechnologyFaculty of ChemistryBielefeld UniversityUniversitätsstr. 2533615BielefeldGermany
| | | | | | - Helmut Schwab
- Institute of Molecular BiotechnologyGraz University of TechnologyPetersgasse 148010GrazAustria
| | - Kerstin Steiner
- Institute of Molecular BiotechnologyGraz University of TechnologyPetersgasse 148010GrazAustria
| |
Collapse
|
6
|
Estupiñán Ó, Rendueles C, Suárez P, Rey V, Murillo D, Morís F, Gutiérrez G, Blanco-López MDC, Matos M, Rodríguez R. Nano-Encapsulation of Mithramycin in Transfersomes and Polymeric Micelles for the Treatment of Sarcomas. J Clin Med 2021; 10:jcm10071358. [PMID: 33806182 PMCID: PMC8037461 DOI: 10.3390/jcm10071358] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 03/13/2021] [Accepted: 03/22/2021] [Indexed: 02/06/2023] Open
Abstract
Sarcomas are aggressive tumors which often show a poor response to current treatments. As a promising therapeutic alternative, we focused on mithramycin (MTM), a natural antibiotic with a promising anti-tumor activity but also a relevant systemic toxicity. Therefore, the encapsulation of MTM in nano-delivery systems may represent a way to increase its therapeutic window. Here, we designed novel transfersomes and PLGA polymeric micelles by combining different membrane components (phosphatidylcholine, Span 60, Tween 20 and cholesterol) to optimize the nanoparticle size, polydispersity index (PDI) and encapsulation efficiency (EE). Using both thin film hydration and the ethanol injection methods we obtained MTM-loaded transferosomes displaying an optimal hydrodynamic diameter of 100–130 nm and EE values higher than 50%. Additionally, we used the emulsion/solvent evaporation method to synthesize polymeric micelles with a mean size of 228 nm and a narrow PDI, capable of encapsulating MTM with EE values up to 87%. These MTM nano-delivery systems mimicked the potent anti-tumor activity of free MTM, both in adherent and cancer stem cell-enriched tumorsphere cultures of myxoid liposarcoma and chondrosarcoma models. Similarly to free MTM, nanocarrier-delivered MTM efficiently inhibits the signaling mediated by the pro-oncogenic factor SP1. In summary, we provide new formulations for the efficient encapsulation of MTM which may constitute a safer delivering alternative to be explored in future clinical uses.
Collapse
Affiliation(s)
- Óscar Estupiñán
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)—Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (Ó.E.); (V.R.); (D.M.)
- Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
- CIBER en Oncología (CIBERONC), 28029 Madrid, Spain
- Department of Chemical and Environmental Engineering, University of Oviedo, 33006 Oviedo, Spain; (C.R.); (P.S.); (G.G.)
| | - Claudia Rendueles
- Department of Chemical and Environmental Engineering, University of Oviedo, 33006 Oviedo, Spain; (C.R.); (P.S.); (G.G.)
| | - Paula Suárez
- Department of Chemical and Environmental Engineering, University of Oviedo, 33006 Oviedo, Spain; (C.R.); (P.S.); (G.G.)
| | - Verónica Rey
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)—Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (Ó.E.); (V.R.); (D.M.)
- Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
| | - Dzohara Murillo
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)—Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (Ó.E.); (V.R.); (D.M.)
| | | | - Gemma Gutiérrez
- Department of Chemical and Environmental Engineering, University of Oviedo, 33006 Oviedo, Spain; (C.R.); (P.S.); (G.G.)
- Asturias University Institute of Biotechnology, University of Oviedo, 33006 Oviedo, Spain;
| | - María del Carmen Blanco-López
- Asturias University Institute of Biotechnology, University of Oviedo, 33006 Oviedo, Spain;
- Department of Physical and Analytical Chemistry, University of Oviedo, 33006 Oviedo, Spain
| | - María Matos
- Department of Chemical and Environmental Engineering, University of Oviedo, 33006 Oviedo, Spain; (C.R.); (P.S.); (G.G.)
- Asturias University Institute of Biotechnology, University of Oviedo, 33006 Oviedo, Spain;
- Correspondence: (M.M.); (R.R.)
| | - René Rodríguez
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)—Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (Ó.E.); (V.R.); (D.M.)
- Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
- CIBER en Oncología (CIBERONC), 28029 Madrid, Spain
- Correspondence: (M.M.); (R.R.)
| |
Collapse
|
7
|
Costales P, Ríos-Lombardía N, Lorenzo-Herrero S, Morís F, González-Sabín J. Novel chiral naphthalimide-cycloalkanediamine conjugates: Design, synthesis and antitumor activity. Bioorg Chem 2021; 112:104859. [PMID: 33836453 DOI: 10.1016/j.bioorg.2021.104859] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 02/18/2021] [Accepted: 03/22/2021] [Indexed: 10/21/2022]
Abstract
A novel series of enantiopure naphthalimide-cycloalkanediamine conjugates were designed, synthetized and evaluated for in vitro cytotoxicity against human colon adenocarcinoma (LoVo), human lung adenocarcinoma (A549), human cervical carcinoma (Hela) and human promyelocytic leukemia cell lines (HL-60). The cytotoxicity of the compounds was highly dependent on size and relative stereochemistry of the cycloalkyl ring as well as length of the spacer. By contrast, any kind of enantioselection was observed for each pair of enantiomers. Flow cytometric analysis indicated that compounds 22 and 23 could effectively induce G2/M arrest in the four previous cell lines despite a mild apoptotic effect.
Collapse
Affiliation(s)
- Paula Costales
- EntreChem SL, Vivero Ciencias de la Salud, Santo Domingo de Guzmán, 33011 Oviedo, Spain
| | | | - Seila Lorenzo-Herrero
- EntreChem SL, Vivero Ciencias de la Salud, Santo Domingo de Guzmán, 33011 Oviedo, Spain
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, Santo Domingo de Guzmán, 33011 Oviedo, Spain
| | - Javier González-Sabín
- EntreChem SL, Vivero Ciencias de la Salud, Santo Domingo de Guzmán, 33011 Oviedo, Spain.
| |
Collapse
|
8
|
Wolański M, Krawiec M, Schwarz PN, Stegmann E, Wohlleben W, Buchmann A, Gross H, Eitel M, Koch P, Botas A, Méndez C, Núñez LE, Morís F, Cortés J, Zakrzewska‐Czerwińska J. A novel LysR-type regulator negatively affects biosynthesis of the immunosuppressant brasilicardin. Eng Life Sci 2021; 21:4-18. [PMID: 33531886 PMCID: PMC7837296 DOI: 10.1002/elsc.202000038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 09/29/2020] [Accepted: 10/08/2020] [Indexed: 11/16/2022] Open
Abstract
Brasilicardin A (BraA) is a promising immunosuppressive compound produced naturally by the pathogenic bacterium Nocardia terpenica IFM 0406. Heterologous host expression of brasilicardin gene cluster showed to be efficient to bypass the safety issues, low production levels and lack of genetic tools related with the use of native producer. Further improvement of production yields requires better understanding of gene expression regulation within the BraA biosynthetic gene cluster (Bra-BGC); however, the only so far known regulator of this gene cluster is Bra12. In this study, we discovered the protein LysRNt, a novel member of the LysR-type transcriptional regulator family, as a regulator of the Bra-BGC. Using in vitro approaches, we identified the gene promoters which are controlled by LysRNt within the Bra-BGC. Corresponding genes encode enzymes involved in BraA biosynthesis as well as the key Bra-BGC regulator Bra12. Importantly, we provide in vivo evidence that LysRNt negatively affects production of brasilicardin congeners in the heterologous host Amycolatopsis japonicum. Finally, we demonstrate that some of the pathway related metabolites, and their chemical analogs, can interact with LysRNt which in turn affects its DNA-binding activity.
Collapse
Affiliation(s)
| | - Michał Krawiec
- Faculty of BiotechnologyUniversity of WrocławWrocławPoland
| | - Paul N. Schwarz
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenTübingenGermany
| | - Evi Stegmann
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenTübingenGermany
- German Centre for Infection Research (DZIF)Partner Site TübingenTübingenGermany
| | - Wolfgang Wohlleben
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenTübingenGermany
- German Centre for Infection Research (DZIF)Partner Site TübingenTübingenGermany
| | - Anina Buchmann
- German Centre for Infection Research (DZIF)Partner Site TübingenTübingenGermany
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenTübingenGermany
- Present address:
Institute of Biochemical EngineeringUniversity of StuttgartStuttgartGermany
| | - Harald Gross
- German Centre for Infection Research (DZIF)Partner Site TübingenTübingenGermany
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenTübingenGermany
| | - Michael Eitel
- Department of Pharmaceutical ChemistryInstitute of Pharmaceutical SciencesUniversity of TübingenTübingenGermany
| | - Pierre Koch
- Department of Pharmaceutical ChemistryInstitute of Pharmaceutical SciencesUniversity of TübingenTübingenGermany
| | - Alma Botas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de AsturiasUniversidad de OviedoOviedoSpain
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de AsturiasUniversidad de OviedoOviedoSpain
| | | | | | | | | |
Collapse
|
9
|
Federico A, Steinfass T, Larribère L, Novak D, Morís F, Núñez LE, Umansky V, Utikal J. Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. Mol Ther Oncolytics 2020; 18:83-99. [PMID: 32637583 PMCID: PMC7327877 DOI: 10.1016/j.omto.2020.06.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 06/01/2020] [Indexed: 12/24/2022]
Abstract
Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting molecular mechanisms driving melanoma progression is essential for the development of more effective targeted therapeutic approaches. Recent studies, including the research previously conducted in our laboratory, reported that the histone methyltransferase SETDB1 contributes to melanoma pathogenesis. In this follow-up study, we further elucidated the role of SETDB1 in melanoma, showing that SETDB1 modulated relevant transcriptomic effects in melanoma, in particular, as activator of cancer-related secreted (CRS) factors and as repressor of melanocyte-lineage differentiation (MLD) and metabolic enzymes. Next, we investigated the effects of SETDB1 inhibition via compounds belonging to the mithramycin family, mithramycin A and mithramycin analog (mithralog) EC-8042: melanoma cells showed strong sensitivity to these drugs, which effectively suppressed the expression of SETDB1 and induced changes at the transcriptomic, morphological, and functional level. Moreover, SETDB1 inhibitors enhanced the efficacy of mitogen-activated protein kinase (MAPK) inhibitor-based therapies against melanoma. Taken together, this work highlights the key regulatory role of SETDB1 in melanoma and supports the development of SETDB1-targeting therapeutic strategies for the treatment of melanoma patients.
Collapse
Affiliation(s)
- Aniello Federico
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Tamara Steinfass
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Lionel Larribère
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Daniel Novak
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain
| | - Luz-Elena Núñez
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain
| | - Viktor Umansky
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| | - Jochen Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120 Baden Württemberg, Germany.,Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, 68135 Baden Württemberg, Germany
| |
Collapse
|
10
|
Ríos-Lombardía N, Rodríguez-Álvarez MJ, Morís F, Kourist R, Comino N, López-Gallego F, González-Sabín J, García-Álvarez J. DESign of Sustainable One-Pot Chemoenzymatic Organic Transformations in Deep Eutectic Solvents for the Synthesis of 1,2-Disubstituted Aromatic Olefins. Front Chem 2020; 8:139. [PMID: 32211377 PMCID: PMC7067824 DOI: 10.3389/fchem.2020.00139] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 02/14/2020] [Indexed: 12/20/2022] Open
Abstract
The self-assembly of styrene-type olefins into the corresponding stilbenes was conveniently performed in the Deep Eutectic Solvent (DES) mixture 1ChCl/2Gly under air and in the absence of hazardous organic co-solvents using a one-pot chemo-biocatalytic route. Here, an enzymatic decarboxylation of p-hydroxycinnamic acids sequentially followed by a ruthenium-catalyzed metathesis of olefins has been investigated in DES. Moreover, and to extend the design of chemoenzymatic processes in DESs, we also coupled the aforementioned enzymatic decarboxylation reaction to now concomitant Pd-catalyzed Heck-type C-C coupling to produce biaryl derivatives under environmentally friendly reaction conditions.
Collapse
Affiliation(s)
| | - María Jesús Rodríguez-Álvarez
- Laboratorio de Compuestos Organometálicos y Catálisis (Unidad Asociada al CSIC), Departamento de Química Orgánica e Inorgánica (IUQOEM), Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Oviedo, Oviedo, Spain
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, Santo Domingo de Guzmán, Oviedo, Spain
| | - Robert Kourist
- Institute of Chemistry, Organic & Bioorganic Chemistry, NAWI Graz, BioTechMed Graz, University of Graz, Graz, Austria
| | - Natalia Comino
- Heterogeneous Biocatalysis Laboratory, CIC biomaGUNE, Donostia-San Sebastian, Spain
| | | | | | - Joaquín García-Álvarez
- Laboratorio de Compuestos Organometálicos y Catálisis (Unidad Asociada al CSIC), Departamento de Química Orgánica e Inorgánica (IUQOEM), Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Oviedo, Oviedo, Spain
| |
Collapse
|
11
|
Affiliation(s)
- Lisa Marx
- Department of Industrial Biotechnology; KTH Royal Institute of Technology; 106 91 Stockholm Sweden
- EntreChem S.L.; 33011 Oviedo Spain
- Enzymicals AG; 17489 Greifswald Germany
| | | | | | - Matthias Höhne
- Institute of Biochemistry; University of Greifswald; 17487 Greifswald Germany
| | | | | | - Per Berglund
- Department of Industrial Biotechnology; KTH Royal Institute of Technology; 106 91 Stockholm Sweden
| |
Collapse
|
12
|
Ríos-Lombardía N, Cicco L, Yamamoto K, Hernández-Fernández JA, Morís F, Capriati V, García-Álvarez J, González-Sabín J. Deep eutectic solvent-catalyzed Meyer-Schuster rearrangement of propargylic alcohols under mild and bench reaction conditions. Chem Commun (Camb) 2020; 56:15165-15168. [PMID: 33215181 DOI: 10.1039/d0cc06584f] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The Meyer-Schuster rearrangement of propargylic alcohols into α,β-unsaturated carbonyl compounds has been revisited by setting up an atom-economic process catalyzed by a deep eutectic solvent FeCl3·6H2O/glycerol. Isomerizations take place smoothly, at room temperature, under air and with short reaction times. The unique solubilizing properties of the eutectic mixture enabled the use of a substrate concentration up to 1.0 M with the medium being recycled up to ten runs without any loss of catalytic activity.
Collapse
Affiliation(s)
- Nicolás Ríos-Lombardía
- EntreChem SL, Vivero Ciencias de la Salud. Santo Domingo de Guzmán, Oviedo, 33011, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Elorriaga D, Rodríguez-Álvarez MJ, Ríos-Lombardía N, Morís F, Presa Soto A, González-Sabín J, Hevia E, García-Álvarez J. Combination of organocatalytic oxidation of alcohols and organolithium chemistry (RLi) in aqueous media, at room temperature and under aerobic conditions. Chem Commun (Camb) 2020; 56:8932-8935. [DOI: 10.1039/d0cc03768k] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Organocatalysis and highly-polar s-block organometallic chemistry (RLi) work together in water, under air and at room temperature for the selective and ultrafast synthesis of tertiary alcohols.
Collapse
Affiliation(s)
- David Elorriaga
- Departamento de Química Orgánica e Inorgánica
- (IUQOEM) Facultad de Química
- Universidad de Oviedo
- Oviedo
- Spain
| | | | | | | | - Alejandro Presa Soto
- Departamento de Química Orgánica e Inorgánica
- (IUQOEM) Facultad de Química
- Universidad de Oviedo
- Oviedo
- Spain
| | | | - Eva Hevia
- Department für Chemie und Biochemie
- Universität Bern
- Bern
- Switzerland
| | - Joaquín García-Álvarez
- Departamento de Química Orgánica e Inorgánica
- (IUQOEM) Facultad de Química
- Universidad de Oviedo
- Oviedo
- Spain
| |
Collapse
|
14
|
Sviatenko O, Ríos‐Lombardía N, Morís F, González‐Sabín J, Venkata Manideep K, Merdivan S, Günther S, Süss P, Höhne M. One‐pot Synthesis of 4‐Aminocyclohexanol Isomers by Combining a Keto Reductase and an Amine Transaminase. ChemCatChem 2019. [DOI: 10.1002/cctc.201900733] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Olha Sviatenko
- Institute of BiochemistryUniversity of Greifswald Felix-Hausdorff-Str. 4 Greifswald 17489 Germany
| | | | - Francisco Morís
- EntreChem SL Vivero Ciencias de la SaludSanto Domingo de Guzmán s/n Oviedo 33011 España
| | - Javier González‐Sabín
- EntreChem SL Vivero Ciencias de la SaludSanto Domingo de Guzmán s/n Oviedo 33011 España
| | | | - Simon Merdivan
- Institute of PharmacyUniversity of Greifswald Friedrich-Ludwig-Jahn-Str. 17 Greifswald 17489 Germany
| | - Sebastian Günther
- Institute of PharmacyUniversity of Greifswald Friedrich-Ludwig-Jahn-Str. 17 Greifswald 17489 Germany
| | - Philipp Süss
- Enzymicals AG Walther-Rathenau-Str. 49a Greifswald 17489 Germany
| | - Matthias Höhne
- Institute of BiochemistryUniversity of Greifswald Felix-Hausdorff-Str. 4 Greifswald 17489 Germany
| |
Collapse
|
15
|
Lorenzo-Herrero S, Sordo-Bahamonde C, Bretones G, Payer ÁR, González-Rodríguez AP, González-García E, Pérez-Escuredo J, Villa-Álvarez M, Núñez LE, Morís F, Gonzalez S, López-Soto A. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling. Front Immunol 2019; 10:2455. [PMID: 31681329 PMCID: PMC6813538 DOI: 10.3389/fimmu.2019.02455] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Accepted: 10/01/2019] [Indexed: 02/01/2023] Open
Abstract
B-cell receptor (BCR)-dependent signaling is central for leukemia B-cell homeostasis, as underscored by the promising clinical results obtained in patients with chronic lymphocytic leukemia (CLL) treated with novel agents targeting components of this pathway. Herein, we demonstrate that the mithralog EC-7072 displays high ex vivo cytotoxic activity against leukemia cells from CLL patients independently from high-risk prognostic markers and IGHV mutational status. EC-7072 was significantly less toxic against T cells and NK cells and did not alter the production of the immune effector molecules IFN-γ and perforin. EC-7072 directly triggered caspase-3-dependent CLL cell apoptosis, which was not abrogated by microenvironment-derived factors that sustain leukemia cell survival. RNA-sequencing analyses revealed a dramatic EC-7072-driven reprograming of the transcriptome of CLL cells, including a wide downregulation of multiple components and targets of the BCR signaling pathway. Accordingly, we found decreased levels of phosphorylated signaling nodes downstream of the BCR. Crosslinking-mediated BCR activation antagonized CLL cell death triggered by EC-7072, increased the phosphorylation levels of the abovementioned signaling nodes and upregulated BCL2 expression, suggesting that the mithralog disrupts CLL cell viability by targeting the BCR signaling axis at multiple levels. EC-7072 exerted similar or higher antileukemic activity than that of several available CLL therapies and displayed additive or synergistic interaction with these drugs in killing CLL cells. Overall, our findings provide rationale for future investigation to test whether EC-7072 may be a potential therapeutic option for patients with CLL and other B-cell malignancies.
Collapse
Affiliation(s)
- Seila Lorenzo-Herrero
- Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Oviedo, Spain.,Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Christian Sordo-Bahamonde
- Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Oviedo, Spain.,Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.,EntreChem S.L., Oviedo, Spain
| | - Gabriel Bretones
- Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.,Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, Oviedo, Spain
| | - Ángel R Payer
- Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.,Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Ana P González-Rodríguez
- Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.,Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | | | - Mónica Villa-Álvarez
- Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Oviedo, Spain.,Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | | | | | - Segundo Gonzalez
- Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Oviedo, Spain.,Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Alejandro López-Soto
- Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Oviedo, Spain.,Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| |
Collapse
|
16
|
Hermida-Prado F, Villaronga MÁ, Granda-Díaz R, Del-Río-Ibisate N, Santos L, Hermosilla MA, Oro P, Allonca E, Agorreta J, Garmendia I, Tornín J, Perez-Escuredo J, Fuente R, Montuenga LM, Morís F, Rodrigo JP, Rodríguez R, García-Pedrero JM. The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042. J Clin Med 2019; 8:jcm8081157. [PMID: 31382448 PMCID: PMC6722627 DOI: 10.3390/jcm8081157] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 07/31/2019] [Indexed: 12/19/2022] Open
Abstract
The frequent dysregulation of SRC family kinases (SFK) in multiple cancers prompted various inhibitors to be actively tested in preclinical and clinical trials. Disappointingly, dasatinib and saracatinib failed to demonstrate monotherapeutic efficacy in patients with head and neck squamous cell carcinomas (HNSCC). Deeper functional and mechanistic knowledge of the actions of these drugs is therefore needed to improve clinical outcome and to develop more efficient combinational strategies. Even though the SFK inhibitors dasatinib and saracatinib robustly blocked cell migration and invasion in HNSCC cell lines, this study unveils undesirable stem cell-promoting functions that could explain the lack of clinical efficacy in HNSCC patients. These deleterious effects were targeted by the mithramycin analog EC-8042 that efficiently eliminated cancer stem cells (CSC)-enriched tumorsphere cultures as well as tumor bulk cells and demonstrated potent antitumor activity in vivo. Furthermore, combination treatment of dasatinib with EC-8042 provided favorable complementary anti-proliferative, anti-invasive, and anti-CSC functions without any noticeable adverse interactions of both agents. These findings strongly support combinational strategies with EC-8042 for clinical testing in HNSCC patients. These data may have implications on ongoing dasatinib-based trials.
Collapse
Affiliation(s)
- Francisco Hermida-Prado
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
| | - M Ángeles Villaronga
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
| | - Rocío Granda-Díaz
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
| | - Nagore Del-Río-Ibisate
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
| | - Laura Santos
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
| | | | - Patricia Oro
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain
| | - Eva Allonca
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
| | - Jackeline Agorreta
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
- Program in Solid Tumors, Center for Applied Medical Research (CIMA), Department of Pathology, Anatomy and Physiology, University of Navarra, and Navarra's Health Research Institute (IDISNA), 31008 Pamplona, Spain
| | - Irati Garmendia
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
- Program in Solid Tumors, Center for Applied Medical Research (CIMA), Department of Pathology, Anatomy and Physiology, University of Navarra, and Navarra's Health Research Institute (IDISNA), 31008 Pamplona, Spain
| | - Juan Tornín
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
| | | | - Rocío Fuente
- Division of Pediatrics, Department of Medicine, Faculty of Medicine, University of Oviedo, 33006 Oviedo, Spain
| | - Luis M Montuenga
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
- Program in Solid Tumors, Center for Applied Medical Research (CIMA), Department of Pathology, Anatomy and Physiology, University of Navarra, and Navarra's Health Research Institute (IDISNA), 31008 Pamplona, Spain
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain
| | - Juan P Rodrigo
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain
| | - René Rodríguez
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain.
| | - Juana M García-Pedrero
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- Ciber de Cáncer, CIBERONC, 28029 Madrid, Spain.
| |
Collapse
|
17
|
Correia Cordeiro RS, Ríos-Lombardía N, Morís F, Kourist R, González-Sabín J. One-Pot Transformation of Ketoximes into Optically Active Alcohols and Amines by Sequential Action of Laccases and Ketoreductases or ω-Transaminases. ChemCatChem 2019. [DOI: 10.1002/cctc.201801900] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Raquel S. Correia Cordeiro
- EntreChem SL; Vivero Ciencias de la Salud 33011 Oviedo Spain
- Junior Research Group for Microbial Biotechnology Faculty of Biology and Biotechnology; Ruhr-University Bochum; Bochum 44780 Germany
| | | | - Francisco Morís
- EntreChem SL; Vivero Ciencias de la Salud 33011 Oviedo Spain
| | - Robert Kourist
- Graz University of Technology; Petersgasse 14 Graz 8010 Austria
| | | |
Collapse
|
18
|
Telzerow A, Paris J, Håkansson M, González-Sabín J, Ríos-Lombardía N, Schürmann M, Gröger H, Morís F, Kourist R, Schwab H, Steiner K. Amine Transaminase from Exophiala Xenobiotica—Crystal Structure and Engineering of a Fold IV Transaminase that Naturally Converts Biaryl Ketones. ACS Catal 2018. [DOI: 10.1021/acscatal.8b04524] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Aline Telzerow
- Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
- InnoSyn B. V., Urmonderbaan 22, 6167RD Geleen, The Netherlands
| | - Juraj Paris
- Chair of Organic Chemistry I, Faculty of Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany
- Entrechem, S.L., Vivero Ciencias de la Salud, Santo Domingo de Guzmán,
s/n, 33011 Oviedo, Spain
| | - Maria Håkansson
- SARomics Biostructures AB, Medicon Village, Scheelevägen 2, 22381 Lund, Sweden
| | - Javier González-Sabín
- Entrechem, S.L., Vivero Ciencias de la Salud, Santo Domingo de Guzmán,
s/n, 33011 Oviedo, Spain
| | - Nicolás Ríos-Lombardía
- Entrechem, S.L., Vivero Ciencias de la Salud, Santo Domingo de Guzmán,
s/n, 33011 Oviedo, Spain
| | | | - Harald Gröger
- Chair of Organic Chemistry I, Faculty of Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany
| | - Francisco Morís
- Entrechem, S.L., Vivero Ciencias de la Salud, Santo Domingo de Guzmán,
s/n, 33011 Oviedo, Spain
| | - Robert Kourist
- Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Helmut Schwab
- Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| | - Kerstin Steiner
- Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria
| |
Collapse
|
19
|
Álvarez-Teijeiro S, García-Inclán C, Villaronga MÁ, Casado P, Hermida-Prado F, Granda-Díaz R, Rodrigo JP, Calvo F, Del-Río-Ibisate N, Gandarillas A, Morís F, Hermsen M, Cutillas P, García-Pedrero JM. Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets. Cancers (Basel) 2018; 10:cancers10090334. [PMID: 30227608 PMCID: PMC6162704 DOI: 10.3390/cancers10090334] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 09/09/2018] [Accepted: 09/12/2018] [Indexed: 12/15/2022] Open
Abstract
This study investigates for the first time the crosstalk between stromal fibroblasts and cancer stem cell (CSC) biology in head and neck squamous cell carcinomas (HNSCC), with the ultimate goal of identifying effective therapeutic targets. The effects of conditioned media from cancer-associated fibroblasts (CAFs) and normal fibroblasts (NFs) on the CSC phenotype were assessed by combining functional and expression analyses in HNSCC-derived cell lines. Further characterization of CAFs and NFs secretomes by mass spectrometry was followed by pharmacologic target inhibition. We demonstrate that factors secreted by CAFs but not NFs, in the absence of serum/supplements, robustly increased anchorage-independent growth, tumorsphere formation, and CSC-marker expression. Modulators of epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR), and platelet-derived growth factor receptor (PDGFR) activity were identified as paracrine cytokines/factors differentially secreted between CAFs and NFs, in a mass spectrometry analysis. Furthermore, pharmacologic inhibition of EGFR, IGFR, and PDGFR significantly reduced CAF-induced tumorsphere formation and anchorage-independent growth suggesting a role of these receptor tyrosine kinases in sustaining the CSC phenotype. These findings provide novel insights into tumor stroma⁻CSC communication, and potential therapeutic targets to effectively block the CAF-enhanced CSC niche signaling circuit.
Collapse
Affiliation(s)
- Saúl Álvarez-Teijeiro
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- CIBERONC, 28029 Madrid, Spain.
| | - Cristina García-Inclán
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
| | - M Ángeles Villaronga
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- CIBERONC, 28029 Madrid, Spain.
| | - Pedro Casado
- Cell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
| | - Francisco Hermida-Prado
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
| | - Rocío Granda-Díaz
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
| | - Juan P Rodrigo
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- CIBERONC, 28029 Madrid, Spain.
| | - Fernando Calvo
- Tumour Microenvironment Team, Division of Cancer Biology, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
| | - Nagore Del-Río-Ibisate
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
| | - Alberto Gandarillas
- Cell Cycle, Stem Cell Fate and Cancer Lab Instituto de Investigación Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, 33011 Oviedo, Spain.
| | - Mario Hermsen
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- CIBERONC, 28029 Madrid, Spain.
| | - Pedro Cutillas
- Cell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
| | - Juana M García-Pedrero
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias; Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
- CIBERONC, 28029 Madrid, Spain.
| |
Collapse
|
20
|
Liardo E, González-Fernández R, Ríos-Lombardía N, Morís F, García-Álvarez J, Cadierno V, Crochet P, Rebolledo F, González-Sabín J. Strengthening the Combination between Enzymes and Metals in Aqueous Medium: Concurrent Ruthenium-Catalyzed Nitrile Hydration - Asymmetric Ketone Bioreduction. ChemCatChem 2018. [DOI: 10.1002/cctc.201801005] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Elisa Liardo
- EntreChem SL; Vivero Ciencias de la Salud; Santo Domingo de Guzmán 33011 Spain
| | - Rebeca González-Fernández
- Laboratorio de Compuestos Organometálicos y Catálisis (Unidad asociada al CSIC) Centro de Innovación en Química Avanzada (ORFEO-CINQA) Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; Oviedo E-33006 Spain
| | | | - Francisco Morís
- EntreChem SL; Vivero Ciencias de la Salud; Santo Domingo de Guzmán 33011 Spain
| | - Joaquín García-Álvarez
- Laboratorio de Compuestos Organometálicos y Catálisis (Unidad asociada al CSIC) Centro de Innovación en Química Avanzada (ORFEO-CINQA) Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; Oviedo E-33006 Spain
| | - Victorio Cadierno
- Laboratorio de Compuestos Organometálicos y Catálisis (Unidad asociada al CSIC) Centro de Innovación en Química Avanzada (ORFEO-CINQA) Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; Oviedo E-33006 Spain
| | - Pascale Crochet
- Laboratorio de Compuestos Organometálicos y Catálisis (Unidad asociada al CSIC) Centro de Innovación en Química Avanzada (ORFEO-CINQA) Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; Oviedo E-33006 Spain
| | - Francisca Rebolledo
- Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; Oviedo E-33006 Spain
| | | |
Collapse
|
21
|
Paris J, Ríos‐Lombardía N, Morís F, Gröger H, González‐Sabín J. Novel Insights into the Combination of Metal‐ and Biocatalysis: Cascade One‐Pot Synthesis of Enantiomerically Pure Biaryl Alcohols in Deep Eutectic Solvents. ChemCatChem 2018. [DOI: 10.1002/cctc.201800768] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Juraj Paris
- Vivero Ciencias de la SaludSanto Domingo de Guzmán 33011 Oviedo Spain
- Chair of Organic Chemistry I Faculty of ChemistryBielefeld University Universitätsstr. 25 33615 Bielefeld Germany
| | | | - Francisco Morís
- Vivero Ciencias de la SaludSanto Domingo de Guzmán 33011 Oviedo Spain
| | - Harald Gröger
- Chair of Organic Chemistry I Faculty of ChemistryBielefeld University Universitätsstr. 25 33615 Bielefeld Germany
| | | |
Collapse
|
22
|
Liardo E, Ríos-Lombardía N, Morís F, González-Sabín J, Rebolledo F. A Straightforward Deracemization of sec
-Alcohols Combining Organocatalytic Oxidation and Biocatalytic Reduction. European J Org Chem 2018. [DOI: 10.1002/ejoc.201800569] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Elisa Liardo
- Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; 33006 Oviedo Spain
| | | | - Francisco Morís
- Vivero Ciencias de la Salud; EntreChem SL; Santo Domingo de Guzmán 33011 Oviedo Spain
| | - Javier González-Sabín
- Vivero Ciencias de la Salud; EntreChem SL; Santo Domingo de Guzmán 33011 Oviedo Spain
| | - Francisca Rebolledo
- Departamento de Química Orgánica e Inorgánica; Universidad de Oviedo; 33006 Oviedo Spain
| |
Collapse
|
23
|
Marx L, Ríos-Lombardía N, Farnberger JF, Kroutil W, Benítez-Mateos AI, López-Gallego F, Morís F, González-Sabín J, Berglund P. Front Cover Picture: Chemoenzymatic Approaches to the Synthesis of the Calcimimetic Agent Cinacalcet Employing Transaminases and Ketoreductases (Adv. Synth. Catal. 11/2018). Adv Synth Catal 2018. [DOI: 10.1002/adsc.201800499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Lisa Marx
- KTH Royal Institute of Technology; Department of Industrial Biotechnology; SE-106 91 Stockholm Sweden
- EntreChem, S.L.; Vivero Ciencias de la Salud; Santo Domingo de Guzmán 33011 Oviedo Spain
| | - Nicolás Ríos-Lombardía
- EntreChem, S.L.; Vivero Ciencias de la Salud; Santo Domingo de Guzmán 33011 Oviedo Spain
| | - Judith F. Farnberger
- Austrian Centre of Industrial Biotechnology; ACIB GmbH; c/o University of Graz; Harrachgasse 21 8010 Graz Austria
| | - Wolfgang Kroutil
- Institute of Chemistry; Organic and Bioorganic Chemistry; University of Graz; Harrachgasse 21 8010 Graz Austria
| | - Ana I. Benítez-Mateos
- Heterogeneous biocatalysis group; CIC biomaGUNE; Edificio Empresarial “C”; Paseo de Miramón 182 20009 Donostia Spain
| | - Fernando López-Gallego
- Heterogeneous biocatalysis group; CIC biomaGUNE; Edificio Empresarial “C”; Paseo de Miramón 182 20009 Donostia Spain
- IKERBASQUE; Basque Foundation for Science; Bilbao Spain
| | - Francisco Morís
- EntreChem, S.L.; Vivero Ciencias de la Salud; Santo Domingo de Guzmán 33011 Oviedo Spain
| | - Javier González-Sabín
- EntreChem, S.L.; Vivero Ciencias de la Salud; Santo Domingo de Guzmán 33011 Oviedo Spain
| | - Per Berglund
- KTH Royal Institute of Technology; Department of Industrial Biotechnology; SE-106 91 Stockholm Sweden
| |
Collapse
|
24
|
Marx L, Ríos‐Lombardía N, Farnberger JF, Kroutil W, Benítez‐Mateos AI, López‐Gallego F, Morís F, González‐Sabín J, Berglund P. Chemoenzymatic Approaches to the Synthesis of the Calcimimetic Agent Cinacalcet Employing Transaminases and Ketoreductases. Adv Synth Catal 2018; 360:2157-2165. [PMID: 29937706 PMCID: PMC6001662 DOI: 10.1002/adsc.201701485] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 02/05/2018] [Indexed: 12/16/2022]
Abstract
Several chemoenzymatic routes have been explored for the preparation of cinacalcet, a calcimimetic agent. Transaminases (TAs) and ketoreductases (KREDs) turned out to be useful biocatalysts for the preparation of key optically active precursors. Thus, the asymmetric amination of 1-acetonaphthone yielded an enantiopure (R)-amine, which can be alkylated in one step to yield cinacalcet. Alternatively, the bioreduction of the same ketone resulted in an enantiopure (S)-alcohol, which was easily converted into the previous (R)-amine. In addition, the reduction was efficiently performed with the KRED and its cofactor co-immobilized on the same porous surface. This self-sufficient heterogeneous biocatalyst presented an accumulated total turnover number (TTN) for the cofactor of 675 after 5 consecutive operational cycles. Finally, in a preparative scale synthesis the TA-based approach was performed in aqueous medium and led to enantiopure cinacalcet in two steps and 50% overall yield.
Collapse
Affiliation(s)
- Lisa Marx
- KTH Royal Institute of TechnologyDepartment of Industrial BiotechnologySE-106 91StockholmSweden
- EntreChem, S.L.Vivero Ciencias de la SaludSanto Domingo de Guzmán33011OviedoSpain
| | | | - Judith F. Farnberger
- Austrian Centre of Industrial BiotechnologyACIB GmbHc/o University of GrazHarrachgasse 218010GrazAustria
| | - Wolfgang Kroutil
- Institute of ChemistryOrganic and Bioorganic ChemistryUniversity of GrazHarrachgasse 218010GrazAustria
| | - Ana I. Benítez‐Mateos
- Heterogeneous biocatalysis groupCIC biomaGUNEEdificio Empresarial “C”Paseo de Miramón 18220009DonostiaSpain
| | - Fernando López‐Gallego
- Heterogeneous biocatalysis groupCIC biomaGUNEEdificio Empresarial “C”Paseo de Miramón 18220009DonostiaSpain
- IKERBASQUEBasque Foundation for ScienceBilbaoSpain
| | - Francisco Morís
- EntreChem, S.L.Vivero Ciencias de la SaludSanto Domingo de Guzmán33011OviedoSpain
| | | | - Per Berglund
- KTH Royal Institute of TechnologyDepartment of Industrial BiotechnologySE-106 91StockholmSweden
| |
Collapse
|
25
|
Sánchez ÓRE, Santos L, Rodríguez A, Costales P, Hermosilla M, Oro P, Rey V, Menéndez S, Morís F, Rodríguez R. PO-008 Anti-tumour properties of novel multikinase inhibitors in sarcomas: synergistic combination with doxorubicin. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
26
|
Ye S, Braña AF, González-Sabín J, Morís F, Olano C, Salas JA, Méndez C. New Insights into the Biosynthesis Pathway of Polyketide Alkaloid Argimycins P in Streptomyces argillaceus. Front Microbiol 2018; 9:252. [PMID: 29503641 PMCID: PMC5820336 DOI: 10.3389/fmicb.2018.00252] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Accepted: 01/31/2018] [Indexed: 12/18/2022] Open
Abstract
Argimycins P are a recently identified family of polyketide alkaloids encoded by the cryptic gene cluster arp of Streptomyces argillaceus. These compounds contain either a piperideine ring, or a piperidine ring which may be fused to a five membered ring, and a polyene side chain, which is bound in some cases to an N-acetylcysteine moiety. The arp cluster consists of 11 genes coding for structural proteins, two for regulatory proteins and one for a hypothetical protein. Herein, we have characterized the post-piperideine ring biosynthesis steps of argimycins P through the generation of mutants in arp genes, the identification and characterization of compounds accumulated by those mutants, and cross-feeding experiments between mutants. Based in these results, a biosynthesis pathway is proposed assigning roles to every arp gene product. The regulation of the arp cluster is also addressed by inactivating/overexpressing the positive SARP-like arpRI and the negative TetR-like arpRII transcriptional regulators and determining the effect on argimycins P production, and through gene expression analyses (reverse transcription PCR and quantitative real-time PCR) of arp genes in regulatory mutants in comparison to the wild type strain. These findings will contribute to deepen the knowledge on the biosynthesis of piperidine-containing polyketides and provide tools that can be used to generate new analogs by genetic engineering and/or biocatalysis.
Collapse
Affiliation(s)
- Suhui Ye
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Alfredo F Braña
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | | | | | - Carlos Olano
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - José A Salas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.,Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain
| |
Collapse
|
27
|
Puente-Moncada N, Costales P, Antolín I, Núñez LE, Oro P, Hermosilla MA, Pérez-Escuredo J, Ríos-Lombardía N, Sanchez-Sanchez AM, Luño E, Rodríguez C, Martín V, Morís F. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia. Mol Cancer Ther 2018; 17:614-624. [DOI: 10.1158/1535-7163.mct-17-0530] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 10/19/2017] [Accepted: 12/15/2017] [Indexed: 11/16/2022]
|
28
|
Novakova R, Núñez LE, Homerova D, Knirschova R, Feckova L, Rezuchova B, Sevcikova B, Menéndez N, Morís F, Cortés J, Kormanec J. Correction to: Increased heterologous production of the antitumoral polyketide mithramycin a by engineered Streptomyces lividans TK24 strains. Appl Microbiol Biotechnol 2017; 102:871. [PMID: 29279959 DOI: 10.1007/s00253-017-8710-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The original publication contains error error in the Materials and Methods section and in the acknowledgement section.
Collapse
Affiliation(s)
- Renata Novakova
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia
| | - Luz Elena Núñez
- EntreChem SL, Vivero Ciencias de la Salud, c/Colegio Santo, Domingo de Guzmán, 33011, Oviedo, Spain
| | - Dagmar Homerova
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia
| | - Renata Knirschova
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia
| | - Lubomira Feckova
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia
| | - Bronislava Rezuchova
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia
| | - Beatrica Sevcikova
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia
| | - Nuria Menéndez
- EntreChem SL, Vivero Ciencias de la Salud, c/Colegio Santo, Domingo de Guzmán, 33011, Oviedo, Spain
| | - Francisco Morís
- EntreChem SL, Vivero Ciencias de la Salud, c/Colegio Santo, Domingo de Guzmán, 33011, Oviedo, Spain
| | - Jesús Cortés
- EntreChem SL, Vivero Ciencias de la Salud, c/Colegio Santo, Domingo de Guzmán, 33011, Oviedo, Spain.
| | - Jan Kormanec
- Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, 845 51, Bratislava, Slovakia.
| |
Collapse
|
29
|
Novakova R, Núñez LE, Homerova D, Knirschova R, Feckova L, Rezuchova B, Sevcikova B, Menéndez N, Morís F, Cortés J, Kormanec J. Increased heterologous production of the antitumoral polyketide mithramycin A by engineered Streptomyces lividans TK24 strains. Appl Microbiol Biotechnol 2017; 102:857-869. [DOI: 10.1007/s00253-017-8642-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 11/08/2017] [Accepted: 11/09/2017] [Indexed: 12/15/2022]
|
30
|
Benítez-Mateos AI, San Sebastian E, Ríos-Lombardía N, Morís F, González-Sabín J, López-Gallego F. Asymmetric Reduction of Prochiral Ketones by Using Self-Sufficient Heterogeneous Biocatalysts Based on NADPH-Dependent Ketoreductases. Chemistry 2017; 23:16843-16852. [PMID: 28940802 DOI: 10.1002/chem.201703475] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Indexed: 12/13/2022]
Abstract
The development of cell-free and self-sufficient biocatalytic systems represents an emerging approach to address more complex synthetic schemes under nonphysiological conditions. Herein, we report the development of a self-sufficient heterogeneous biocatalyst for the synthesis of chiral alcohols without the need to add an exogenous cofactor. In this work, an NADPH-dependent ketoreductase was primarily stabilized and further co-immobilized with NADPH to catalyze asymmetric reductions without the addition of an exogenous cofactor. As a result, the immobilized cofactor is accessible, and thus, it is recycled inside the porous structure without diffusing out into the bulk, as demonstrated by single-particle in operando studies. This self-sufficient heterogeneous biocatalyst was used and recycled for the asymmetric reduction of eleven carbonyl compounds in a batch reactor without the addition of exogenous NADPH to achieve the corresponding alcohols in 100 % yield and >99 % ee; this high performance was maintained over five consecutive reaction cycles. Likewise, the self-sufficient heterogeneous biocatalyst was integrated into a plug flow reactor for the continuous synthesis of one model secondary alcohol, which gave rise to a space-time yield of 97-112 g L-1 day-1 ; additionally, the immobilized cofactor accumulated a total turnover number of 1076 for 120 h. This is one of the few examples of the successful implementation of continuous reactions in aqueous media catalyzed by cell-free and immobilized systems that integrate both enzymes and cofactors into the solid phase.
Collapse
Affiliation(s)
- Ana I Benítez-Mateos
- Heterogeneous biocatalysis group, CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009, Donostia, Spain
| | - Eneko San Sebastian
- Molecular Imaging Unit, CIC biomaGUNE, Paseo Miramon 182, San Sebastian, Spain
| | | | - Francisco Morís
- EntreChem SL, Edificio Científico Tecnológico, Campus El Cristo, 33006, Oviedo, Spain
| | - Javier González-Sabín
- EntreChem SL, Edificio Científico Tecnológico, Campus El Cristo, 33006, Oviedo, Spain
| | - Fernando López-Gallego
- Heterogeneous biocatalysis group, CIC biomaGUNE, Edificio Empresarial "C", Paseo de Miramón 182, 20009, Donostia, Spain.,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| |
Collapse
|
31
|
Rodríguez-Álvarez MJ, Ríos-Lombardía N, Schumacher S, Pérez-Iglesias D, Morís F, Cadierno V, García-Álvarez J, González-Sabín J. Combination of Metal-Catalyzed Cycloisomerizations and Biocatalysis in Aqueous Media: Asymmetric Construction of Chiral Alcohols, Lactones, and γ-Hydroxy-Carbonyl Compounds. ACS Catal 2017. [DOI: 10.1021/acscatal.7b02183] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- María J. Rodríguez-Álvarez
- Laboratorio
de Compuestos Organometálicos y Catálisis (Unidad Asociada
al CSIC). Departamento de Química Orgánica e Inorgánica
(IUQOEM), Centro de Innovación en Química Avanzada (ORFEO−CINQA),
Facultad de Química, Universidad de Oviedo, E-33071 Oviedo, Spain
| | | | - Sören Schumacher
- Laboratorio
de Compuestos Organometálicos y Catálisis (Unidad Asociada
al CSIC). Departamento de Química Orgánica e Inorgánica
(IUQOEM), Centro de Innovación en Química Avanzada (ORFEO−CINQA),
Facultad de Química, Universidad de Oviedo, E-33071 Oviedo, Spain
| | - David Pérez-Iglesias
- Laboratorio
de Compuestos Organometálicos y Catálisis (Unidad Asociada
al CSIC). Departamento de Química Orgánica e Inorgánica
(IUQOEM), Centro de Innovación en Química Avanzada (ORFEO−CINQA),
Facultad de Química, Universidad de Oviedo, E-33071 Oviedo, Spain
| | - Francisco Morís
- EntreChem SL, Edificio Científico Tecnológico, Campus El Cristo, 33006 Oviedo, Spain
| | - Victorio Cadierno
- Laboratorio
de Compuestos Organometálicos y Catálisis (Unidad Asociada
al CSIC). Departamento de Química Orgánica e Inorgánica
(IUQOEM), Centro de Innovación en Química Avanzada (ORFEO−CINQA),
Facultad de Química, Universidad de Oviedo, E-33071 Oviedo, Spain
| | - Joaquín García-Álvarez
- Laboratorio
de Compuestos Organometálicos y Catálisis (Unidad Asociada
al CSIC). Departamento de Química Orgánica e Inorgánica
(IUQOEM), Centro de Innovación en Química Avanzada (ORFEO−CINQA),
Facultad de Química, Universidad de Oviedo, E-33071 Oviedo, Spain
| | - Javier González-Sabín
- EntreChem SL, Edificio Científico Tecnológico, Campus El Cristo, 33006 Oviedo, Spain
| |
Collapse
|
32
|
Liardo E, Ríos-Lombardía N, Morís F, Rebolledo F, González-Sabín J. Hybrid Organo- and Biocatalytic Process for the Asymmetric Transformation of Alcohols into Amines in Aqueous Medium. ACS Catal 2017. [DOI: 10.1021/acscatal.7b01543] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Elisa Liardo
- EntreChem SL,
Edificio Científico Tecnológico, Campus El Cristo, 33006 Oviedo, Spain
- Department
of Organic and Inorganic Chemistry, University of Oviedo, Julián Clavería, 8, 33006 Oviedo, Spain
| | | | - Francisco Morís
- EntreChem SL,
Edificio Científico Tecnológico, Campus El Cristo, 33006 Oviedo, Spain
| | - Francisca Rebolledo
- Department
of Organic and Inorganic Chemistry, University of Oviedo, Julián Clavería, 8, 33006 Oviedo, Spain
| | - Javier González-Sabín
- EntreChem SL,
Edificio Científico Tecnológico, Campus El Cristo, 33006 Oviedo, Spain
| |
Collapse
|
33
|
Ye S, Molloy B, Braña AF, Zabala D, Olano C, Cortés J, Morís F, Salas JA, Méndez C. Identification by Genome Mining of a Type I Polyketide Gene Cluster from Streptomyces argillaceus Involved in the Biosynthesis of Pyridine and Piperidine Alkaloids Argimycins P. Front Microbiol 2017; 8:194. [PMID: 28239372 PMCID: PMC5300972 DOI: 10.3389/fmicb.2017.00194] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 01/26/2017] [Indexed: 12/21/2022] Open
Abstract
Genome mining of the mithramycin producer Streptomyces argillaceus ATCC 12956 revealed 31 gene clusters for the biosynthesis of secondary metabolites, and allowed to predict the encoded products for 11 of these clusters. Cluster 18 (renamed cluster arp) corresponded to a type I polyketide gene cluster related to the previously described coelimycin P1 and streptazone gene clusters. The arp cluster consists of fourteen genes, including genes coding for putative regulatory proteins (a SARP-like transcriptional activator and a TetR-like transcriptional repressor), genes coding for structural proteins (three PKSs, one aminotransferase, two dehydrogenases, two cyclases, one imine reductase, a type II thioesterase, and a flavin reductase), and one gene coding for a hypothetical protein. Identification of encoded compounds by this cluster was achieved by combining several strategies: (i) inactivation of the type I PKS gene arpPIII; (ii) inactivation of the putative TetR-transcriptional repressor arpRII; (iii) cultivation of strains in different production media; and (iv) using engineered strains with higher intracellular concentration of malonyl-CoA. This has allowed identifying six new alkaloid compounds named argimycins P, which were purified and structurally characterized by mass spectrometry and nuclear magnetic resonance spectroscopy. Some argimycins P showed a piperidine ring with a polyene side chain (argimycin PIX); others contain also a fused five-membered ring (argimycins PIV-PVI). Argimycins PI-PII showed a pyridine ring instead, and an additional N-acetylcysteinyl moiety. These compounds seem to play a negative role in growth and colony differentiation in S. argillaceus, and some of them show weak antibiotic activity. A pathway for the biosynthesis of argimycins P is proposed, based on the analysis of proposed enzyme functions and on the structure of compounds encoded by the arp cluster.
Collapse
Affiliation(s)
- Suhui Ye
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| | - Brian Molloy
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| | - Alfredo F Braña
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| | - Daniel Zabala
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| | - Carlos Olano
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| | | | | | - José A Salas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo Oviedo, Spain
| |
Collapse
|
34
|
Pedragosa-Moreau S, Le Flohic A, Thienpondt V, Lefoulon F, Petit AM, Ríos-Lombardía N, Morís F, González-Sabín J. Exploiting the Biocatalytic Toolbox for the Asymmetric Synthesis of the Heart-Rate Reducing Agent Ivabradine. Adv Synth Catal 2017. [DOI: 10.1002/adsc.201601222] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
| | | | | | - François Lefoulon
- Technologie Servier; Research and Biopharmacy Centre; 27 rue Eugène Vignat 45000 Orléans France
| | - Anne-Marie Petit
- Technologie Servier; Research and Biopharmacy Centre; 27 rue Eugène Vignat 45000 Orléans France
| | | | - Francisco Morís
- EntreChem, S.L.; Edificio Científico Tecnológico; Campus El Cristo 33006 Oviedo Spain
| | - Javier González-Sabín
- EntreChem, S.L.; Edificio Científico Tecnológico; Campus El Cristo 33006 Oviedo Spain
| |
Collapse
|
35
|
Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A. Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. Oncotarget 2016; 6:31272-83. [PMID: 26418718 PMCID: PMC4741604 DOI: 10.18632/oncotarget.5211] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 09/10/2015] [Indexed: 12/31/2022] Open
Abstract
Protein kinases play a central role in the oncogenesis of colorectal tumors and are attractive druggable targets. Detection of activated kinases within a tumor could open avenues for drug selection and optimization of new kinase inhibitors. By using a phosphokinase arrays with human colorectal tumors we identified activated kinases, including the Epidermal Growth Factor Receptor (EGFR), components of the PI3K/mTOR pathway (AKT and S6), and STAT, among others. A pharmacological screening with kinase inhibitors against these proteins helped us to identify a new kinase inhibitor, termed EC-70124 that showed the highest anti-proliferative activity in cell lines. EC-70124 also inhibited cell migration and biochemical experiments demonstrated its effect targeting the PI3K/mTOR pathway. This drug also arrested cells at G2/M and induced apoptosis. Experiments in combination with standard chemotherapy used in the clinical setting indicated a synergistic effect. EC-70124 also reduced tumor growth in vivo and inhibited pS6 in the implanted tumors. In conclusion, by studying the kinase profile of colorectal tumors, we identified relevant activated pathways, and a new multi-kinase compound with significant antitumor properties.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Alberto Ocaña
- Translational Research Unit, Albacete University Hospital, Albacete, Spain
| |
Collapse
|
36
|
Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A. Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. Oncotarget 2016; 6:27923-37. [PMID: 26314846 PMCID: PMC4695035 DOI: 10.18632/oncotarget.4736] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Accepted: 07/31/2015] [Indexed: 12/30/2022] Open
Abstract
Disseminated triple negative breast cancer (TNBC) is an incurable disease with limited therapeutic options beyond chemotherapy. Therefore, identification of druggable vulnerabilities is an important aim. Protein kinases play a central role in cancer and particularly in TNBC. They are involved in many oncogenic functions including migration, proliferation, genetic stability or maintenance of stem-cell like properties. In this article we describe a novel multi-kinase inhibitor with antitumor activity in this cancer subtype. EC-70124 is a hybrid indolocarbazole analog obtained by combinatorial biosynthesis of Rebeccamycin and Staurosporine genes that showed antiproliferative effect and in vivo antitumoral activity. Biochemical experiments demonstrated the inhibition of the PI3K/mTOR and JAK/STAT pathways. EC-70124 mediated DNA damage leading to cell cycle arrest at the G2/M phase. Pathway analyses identified several deregulated functions including cell proliferation, migration, DNA damage, regulation of stem cell differentiation and reversion of the epithelial-mesenchymal transition (EMT) phenotype, among others. Combination studies showed a synergistic interaction of EC-70124 with docetaxel, and an enhanced activity in vivo. Furthermore, EC-70124 had a good pharmacokinetic profile. In conclusion these experiments demonstrate the antitumor activity of EC-70124 in TNBC paving the way for the future clinical development of this drug alone or in combination with chemotherapy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Gary D Bader
- The Donnelly Centre, University of Toronto, Toronto, Canada
| | | | - Alberto Ocaña
- Translational Research Unit, Albacete University Hospital, Albacete, Spain
| |
Collapse
|
37
|
Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clin Cancer Res 2016; 22:4105-18. [PMID: 26979396 PMCID: PMC4987166 DOI: 10.1158/1078-0432.ccr-15-2624] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 02/18/2016] [Indexed: 12/22/2022]
Abstract
PURPOSE The goal of this study was to identify second-generation mithramycin analogues that better target the EWS-FLI1 transcription factor for Ewing sarcoma. We previously established mithramycin as an EWS-FLI1 inhibitor, but the compound's toxicity prevented its use at effective concentrations in patients. EXPERIMENTAL DESIGN We screened a panel of mithralogs to establish their ability to inhibit EWS-FLI1 in Ewing sarcoma. We compared the IC50 with the MTD established in mice to determine the relationship between efficacy and toxicity. We confirmed the suppression of EWS-FLI1 at the promoter, mRNA, gene signature, and protein levels. We established an improved therapeutic window by using time-lapse microscopy to model the effects on cellular proliferation in Ewing sarcoma cells relative to HepG2 control cells. Finally, we established an improved therapeutic window using a xenograft model of Ewing sarcoma. RESULTS EC-8105 was found to be the most potent analogue and was able to suppress EWS-FLI1 activity at concentrations nontoxic to other cell types. EC-8042 was substantially less toxic than mithramycin in multiple species but maintained suppression of EWS-FLI1 at similar concentrations. Both compounds markedly suppressed Ewing sarcoma xenograft growth and inhibited EWS-FLI1 in vivo CONCLUSIONS These results provide a basis for the continued development of EC-8042 and EC-8105 as EWS-FLI1 inhibitors for the clinic. Clin Cancer Res; 22(16); 4105-18. ©2016 AACR.
Collapse
MESH Headings
- Animals
- Antibiotics, Antineoplastic/pharmacology
- Cell Line, Tumor
- Disease Models, Animal
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Mice
- Molecular Targeted Therapy
- Oncogene Proteins, Fusion/antagonists & inhibitors
- Oncogene Proteins, Fusion/metabolism
- Plicamycin/pharmacology
- Promoter Regions, Genetic
- Proto-Oncogene Protein c-fli-1/antagonists & inhibitors
- Proto-Oncogene Protein c-fli-1/metabolism
- RNA-Binding Protein EWS/antagonists & inhibitors
- RNA-Binding Protein EWS/metabolism
- Sarcoma, Ewing/drug therapy
- Sarcoma, Ewing/genetics
- Sarcoma, Ewing/metabolism
- Sarcoma, Ewing/mortality
- Transcription Factors
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Christy L Osgood
- Division of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Nichole Maloney
- Division of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Christopher G Kidd
- Division of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee
| | | | - Laura Segars
- Division of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee. Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
| | - Meti Gebregiorgis
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
| | - Girma M Woldemichael
- Basic Science Program, Leidos Biomedical Research Laboratory, Inc., Molecular Targets Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Min He
- Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Savita Sankar
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri
| | - Stephen L Lessnick
- Center for Childhood Cancer and Blood Disorders, Nationwide Children's Hospital, Division of Pediatric Hematology/Oncology/BMT, The Ohio State University, Columbus, Ohio
| | - Min Kang
- Texas Tech University Health Science Center, School of Medicine, Lubbock, Texas
| | - Malcolm Smith
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland. Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Lisa Turner
- Van Andel Research Institute, Grand Rapids, Michigan
| | | | - Mary E Winn
- Van Andel Research Institute, Grand Rapids, Michigan
| | | | | | - Lee J Helman
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland
| | | | - Patrick J Grohar
- Division of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee. Van Andel Research Institute, Grand Rapids, Michigan. Helen De Vos Children's Hospital, Grand Rapids, Michigan. Department of Pediatrics, Michigan State University School of Medicine, East Lansing, Michigan.
| |
Collapse
|
38
|
Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. Oncotarget 2016; 6:32856-67. [PMID: 26439989 PMCID: PMC4741734 DOI: 10.18632/oncotarget.5942] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 08/26/2015] [Indexed: 12/16/2022] Open
Abstract
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite response to chemotherapy, relapses are frequent and resistance to available treatments is often observed in the metastatic setting. Therefore, identification of new therapeutic strategies is required. Here we have investigated the effect of the mithramycin analog EC-8042 (demycarosil-3D-β-D-digitoxosyl mithramycin SK) on TNBC. The drug caused a dose-dependent inhibition of proliferation of a set of TNBC cell lines in vitro, and decreased tumor growth in mice xenografted with TNBC cells. Mechanistically, EC-8042 caused an arrest in the G2 phase of the cell cycle, coincident with an increase in pCDK1 and Wee1 levels in cells treated with the drug. In addition, prolonged treatment with the drug also causes apoptosis, mainly through caspase-independent routes. Importantly, EC-8042 synergized with drugs commonly used in the therapy of TNBC in vitro, and potentiated the antitumoral effect of docetaxel in vivo. Together, these data suggest that the mithralog EC-8042 exerts an antitumoral action on TNBC cells and reinforces the action of standard of care drugs used in the therapy of this disease. These characteristics, together with a better toxicology profile of EC-8042 with respect to mithramycin, open the possibility of its clinical evaluation.
Collapse
Affiliation(s)
- Atanasio Pandiella
- Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | | | - Alberto Ocaña
- Translational Research Unit, Complejo Hospitalario Universitario de Albacete, Albacete, Spain
| | | | - Juan C Montero
- Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| |
Collapse
|
39
|
Liardo E, Ríos-Lombardía N, Morís F, González-Sabín J, Rebolledo F. Developing a Biocascade Process: Concurrent Ketone Reduction-Nitrile Hydrolysis of 2-Oxocycloalkanecarbonitriles. Org Lett 2016; 18:3366-9. [DOI: 10.1021/acs.orglett.6b01510] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Elisa Liardo
- Departament of Organic and Inorganic Chemistry, University of Oviedo, Julián Clavería, 8, 33006 Oviedo, Spain
| | | | - Francisco Morís
- EntreChem, SL, Edificio Científico Tecnológico, Campus El Cristo, E-33006 Oviedo, Spain
| | - Javier González-Sabín
- EntreChem, SL, Edificio Científico Tecnológico, Campus El Cristo, E-33006 Oviedo, Spain
| | - Francisca Rebolledo
- Departament of Organic and Inorganic Chemistry, University of Oviedo, Julián Clavería, 8, 33006 Oviedo, Spain
| |
Collapse
|
40
|
Martinez-Cruzado L, Tornin J, Santos L, Rodriguez A, García-Castro J, Morís F, Rodriguez R. Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations. Sci Rep 2016; 6:27878. [PMID: 27292183 PMCID: PMC4904413 DOI: 10.1038/srep27878] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 05/25/2016] [Indexed: 12/11/2022] Open
Abstract
Tumors evolve from initial tumorigenic events into increasingly aggressive behaviors in a process usually driven by subpopulations of cancer stem cells (CSCs). Mesenchymal stromal/stem cells (MSCs) may act as the cell-of-origin for sarcomas, and CSCs that present MSC features have been identified in sarcomas due to their ability to grow as self-renewed floating spheres (tumorspheres). Accordingly, we previously developed sarcoma models using human MSCs transformed with relevant oncogenic events. To study the evolution/emergence of CSC subpopulations during tumor progression, we compared the tumorigenic properties of bulk adherent cultures and tumorsphere-forming subpopulations both in the sarcoma cell-of-origin models (transformed MSCs) and in their corresponding tumor xenograft-derived cells. Tumor formation assays showed that the tumorsphere cultures from xenograft-derived cells, but not from the cell-of-origin models, were enriched in CSCs, providing evidence of the emergence of bona fide CSCs subpopulations during tumor progression. Relevant CSC-related factors, such as ALDH1 and SOX2, were increasingly upregulated in CSCs during tumor progression, and importantly, the increased levels and activity of ALDH1 in these subpopulations were associated with enhanced tumorigenicity. In addition to being a CSC marker, our findings indicate that ALDH1 could also be useful for tracking the malignant potential of CSC subpopulations during sarcoma evolution.
Collapse
Affiliation(s)
- Lucia Martinez-Cruzado
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Juan Tornin
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Laura Santos
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Aida Rodriguez
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Javier García-Castro
- Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
| | | | - Rene Rodriguez
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| |
Collapse
|
41
|
Ríos-Lombardía N, Vidal C, Liardo E, Morís F, García-Álvarez J, González-Sabín J. From a Sequential to a Concurrent Reaction in Aqueous Medium: Ruthenium-Catalyzed Allylic Alcohol Isomerization and Asymmetric Bioreduction. Angew Chem Int Ed Engl 2016; 55:8691-5. [DOI: 10.1002/anie.201601840] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Indexed: 01/25/2023]
Affiliation(s)
| | - Cristian Vidal
- Laboratorio de Compuestos OrganometálicosyCatálisis (Unidad Asociada al CSIC); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Departamento de Química Orgánica e Inorgánica; Facultad de Química; Universidad de Oviedo; 33071 Oviedo Spain
| | - Elisa Liardo
- EntreChem SL; Edificio Científico Tecnológico; Campus El Cristo 33006 Oviedo Spain
| | - Francisco Morís
- EntreChem SL; Edificio Científico Tecnológico; Campus El Cristo 33006 Oviedo Spain
| | - Joaquín García-Álvarez
- Laboratorio de Compuestos OrganometálicosyCatálisis (Unidad Asociada al CSIC); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Departamento de Química Orgánica e Inorgánica; Facultad de Química; Universidad de Oviedo; 33071 Oviedo Spain
| | | |
Collapse
|
42
|
Ríos-Lombardía N, Vidal C, Liardo E, Morís F, García-Álvarez J, González-Sabín J. From a Sequential to a Concurrent Reaction in Aqueous Medium: Ruthenium-Catalyzed Allylic Alcohol Isomerization and Asymmetric Bioreduction. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201601840] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
| | - Cristian Vidal
- Laboratorio de Compuestos OrganometálicosyCatálisis (Unidad Asociada al CSIC); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Departamento de Química Orgánica e Inorgánica; Facultad de Química; Universidad de Oviedo; 33071 Oviedo Spain
| | - Elisa Liardo
- EntreChem SL; Edificio Científico Tecnológico; Campus El Cristo 33006 Oviedo Spain
| | - Francisco Morís
- EntreChem SL; Edificio Científico Tecnológico; Campus El Cristo 33006 Oviedo Spain
| | - Joaquín García-Álvarez
- Laboratorio de Compuestos OrganometálicosyCatálisis (Unidad Asociada al CSIC); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Departamento de Química Orgánica e Inorgánica; Facultad de Química; Universidad de Oviedo; 33071 Oviedo Spain
| | | |
Collapse
|
43
|
Tornin J, Martinez-Cruzado L, Santos L, Rodriguez A, Núñez LE, Oro P, Hermosilla MA, Allonca E, Fernández-García MT, Astudillo A, Suarez C, Morís F, Rodriguez R. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma. Oncotarget 2016; 7:30935-50. [PMID: 27105533 PMCID: PMC5058729 DOI: 10.18632/oncotarget.8817] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 03/28/2016] [Indexed: 12/13/2022] Open
Abstract
Tumor initiating cells (TICs), responsible for tumor initiation, and cancer stem cells (CSCs), responsible for tumor expansion and propagation, are often resistant to chemotherapeutic agents. To find therapeutic targets against sarcoma initiating and propagating cells we used models of myxoid liposarcoma (MLS) and undifferentiated pleomorphic sarcoma (UPS) developed from human mesenchymal stromal/stem cells (hMSCs), which constitute the most likely cell-of-origin for sarcoma. We found that SP1-mediated transcription was among the most significantly altered signaling. To inhibit SP1 activity, we used EC-8042, a mithramycin (MTM) analog (mithralog) with enhanced anti-tumor activity and highly improved safety. EC-8042 inhibited the growth of TIC cultures, induced cell cycle arrest and apoptosis and upregulated the adipogenic factor CEBPα. SP1 knockdown was able to mimic the anti-proliferative effects induced by EC-8042. Importantly, EC-8042 was not recognized as a substrate by several ABC efflux pumps involved in drug resistance, and, opposite to the chemotherapeutic drug doxorubicin, repressed the expression of many genes responsible for the TIC/CSC phenotype, including SOX2, C-MYC, NOTCH1 and NFκB1. Accordingly, EC-8042, but not doxorubicin, efficiently reduced the survival of CSC-enriched tumorsphere sarcoma cultures. In vivo, EC-8042 induced a profound inhibition of tumor growth associated to a strong reduction of the mitotic index and the induction of adipogenic differentiation and senescence. Finally, EC-8042 reduced the ability of tumor cells to reinitiate tumor growth. These data suggest that EC-8042 could constitute an effective treatment against both TIC and CSC subpopulations in sarcoma.
Collapse
Affiliation(s)
- Juan Tornin
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Lucia Martinez-Cruzado
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Laura Santos
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | - Aida Rodriguez
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | | | | | | | - Eva Allonca
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | | | - Aurora Astudillo
- Servicio de Anatomía Patológica, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Carlos Suarez
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| | | | - Rene Rodriguez
- Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
| |
Collapse
|
44
|
Ríos-Lombardía N, Vidal C, Cocina M, Morís F, García-Álvarez J, González-Sabín J. Chemoenzymatic one-pot synthesis in an aqueous medium: combination of metal-catalysed allylic alcohol isomerisation-asymmetric bioamination. Chem Commun (Camb) 2016; 51:10937-40. [PMID: 26062926 DOI: 10.1039/c5cc03298a] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The ruthenium-catalysed isomerisation of allylic alcohols was coupled, for the first time, with asymmetric bioamination in a one-pot process in an aqueous medium. In the cases involving prochiral ketones, the ω-TA exhibited excellent enantioselectivity, identical to that observed in the single step. As a result, amines were obtained from allylic alcohols with high overall yields and excellent enantiomeric excesses.
Collapse
|
45
|
Civenni G, Longoni N, Costales P, Dallavalle C, García Inclán C, Albino D, Nuñez LE, Morís F, Carbone GM, Catapano CV. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB. Mol Cancer Ther 2016; 15:806-18. [PMID: 26826115 DOI: 10.1158/1535-7163.mct-15-0791] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 01/08/2016] [Indexed: 11/16/2022]
Abstract
Cancer stem cells (CSC) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance to current therapies. The transcription factors NF-κB and STAT3 are frequently activated in advanced prostate cancer and sustain expansion of prostate CSCs. EC-70124 is a novel chimeric indolocarbazole compound generated by metabolic engineering of the biosynthetic pathways of glycosylated indolocarbazoles, such as staurosporine and rebeccamycin. In vitro kinome analyses revealed that EC-70124 acted as a multikinase inhibitor with potent activity against IKKβ and JAK2. In this study, we show that EC-70124 blocked concomitantly NF-κB and STAT3 in prostate cancer cells and particularly prostate CSCs, which exhibited overactivation of these transcription factors. Phosphorylation of IkB and STAT3 (Tyr705), the immediate targets of IKKβ and JAK2, respectively, was rapidly inhibited in vitro by EC-70124 at concentrations that were well below plasma levels in mice. Furthermore, the drug blocked activation of NF-κB and STAT3 reporters and suppressed transcription of their target genes. Treatment with EC-70124 impaired proliferation and colony formation in vitro and delayed development of prostate tumor xenografts. Notably, EC-70124 had profound effects on the prostate CSC subpopulation both in vitro and in vivo Thus, EC-70124 is a potent inhibitor of the NF-κB and STAT3 signaling pathways and blocked tumor growth and maintenance of prostate CSCs. EC-70124 may provide the basis for developing new therapeutic strategies that combine agents directed to the CSC component and the bulk tumor cell population for treatment of advanced prostate cancer. Mol Cancer Ther; 15(5); 806-18. ©2016 AACR.
Collapse
Affiliation(s)
- Gianluca Civenni
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland
| | - Nicole Longoni
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland
| | - Paula Costales
- Campus El Cristo, EntreChem, S.L., Edificio Científico Tecnológico, Oviedo, Spain
| | - Cecilia Dallavalle
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland
| | - Cristina García Inclán
- Department of Otolaryngology, IUOPA, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - Domenico Albino
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland
| | - Luz Elena Nuñez
- Campus El Cristo, EntreChem, S.L., Edificio Científico Tecnológico, Oviedo, Spain
| | - Francisco Morís
- Campus El Cristo, EntreChem, S.L., Edificio Científico Tecnológico, Oviedo, Spain
| | - Giuseppina M Carbone
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland. Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
| | - Carlo V Catapano
- Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland. Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland. Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
| |
Collapse
|
46
|
Fernández-Guizán A, López-Soto A, Acebes-Huerta A, Huergo-Zapico L, Villa-Álvarez M, Núñez LE, Morís F, Gonzalez S. Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042). PLoS One 2015; 10:e0140786. [PMID: 26536461 PMCID: PMC4633274 DOI: 10.1371/journal.pone.0140786] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 09/30/2015] [Indexed: 12/27/2022] Open
Abstract
Demycarosyl-3D-ß-D-digitoxosyl-mithramycin SK (DIG-MSK) is a recently isolated analogue of mithramycin A (MTA) that showed differences with MTA in the DNA binding strength and selectivity. These differences correlated with a better therapeutic index and less toxicity in animal studies. Herein, we show that DIG-MSK displays a potent anti-tumor activity against different types of cancer cell lines, ovarian tumor cells being particularly sensitive to this drug. Of relevance, DIG-MSK exerts low toxicity on fibroblasts and peripheral blood mononuclear cells, this toxicity being significantly lower than that of MTA. In correlation with its antitumor activity, DIG-MSK strongly inhibited Sp1-mediated transcription and endogenous Sp1 mRNA expression, which correlated with the inhibition of the expression of key Sp1-regulated genes involved in tumorigenesis, including VEGFA, BCL2L1 (Bcl-XL), hTERT, BRCA2, MYC and SRC in several ovarian cells. Significantly, DIG-MSK was a stronger inhibitor of VEGFA expression than MTA. Accordingly, DIG-MSK also exhibited potent anti-angiogenic activity on microvascular endothelial cells. Likewise, it significantly inhibited the gene expression of VEGFR1, VEGFR2, FGFR, PDGFB and PDGFRA and, additionally, it induced the expression of the anti-angiogenic factors angiostatin and tunstatin. These effects correlated with a pro-apoptotic effect on proliferating microvascular endothelial cells and the inhibition of the formation of endothelial capillary structures. Overall, the pleiotropic activity of DIG-MSK in inhibiting key oncogenic and angiogenic pathways, together with its low toxicity profile, highlight the therapeutic potential of this new drug.
Collapse
Affiliation(s)
| | - Alejandro López-Soto
- Department of Functional Biology, IUOPA, Universidad de Oviedo, Oviedo, Spain
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | | | | | | | | | - Segundo Gonzalez
- Department of Functional Biology, IUOPA, Universidad de Oviedo, Oviedo, Spain
| |
Collapse
|
47
|
Méndez C, González-Sabín J, Morís F, Salas JA. Expanding the Chemical Diversity of the Antitumoral Compound Mithramycin by Combinatorial Biosynthesis and Biocatalysis: The Quest for Mithralogs with Improved Therapeutic Window. Planta Med 2015; 81:1326-1338. [PMID: 26393942 DOI: 10.1055/s-0035-1557876] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Mithramycin is an antitumor compound of the aureolic acid family produced by Streptomyces argillaceus. It has been used to treat several types of cancer including testicular carcinoma, chronic and acute myeloid leukemia as well as hypercalcemias and Paget's disease. Although the use of mithramycin in humans has been limited because its side effects, in recent years a renewed interest has arisen since new uses and activities have been ascribed to it. Chemically, mithramycin is characterized by a tricyclic aglycone bearing two aliphatic side chains attached at C3 and C7, and disaccharide and trisaccharide units attached at positions 2 and 6, respectively. The mithramycin gene cluster has been characterized. This has allowed for the development of several mithramycin analogs ("mithralogs") by combinatorial biosynthesis and/or biocatalysis. The combinatorial biosynthesis strategies include gene inactivation and/or the use of sugar biosynthesis plasmids for sugar modification. In addition, lipase-based biocatalysis enabled selective modifications of the hydroxyl groups, providing further mithramycin analogs. As a result, new mithramycin analogs with higher antitumor activity and/or less toxicity have been generated. One, demycarosyl-3D-β-D-digitoxosyl-mithramycin SK (EC-8042), is being tested in regulatory preclinical assays, representing an opportunity to open the therapeutic window of this promising molecular scaffold.
Collapse
Affiliation(s)
- Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I. U. O. P.A), Universidad de Oviedo, Oviedo, Spain
| | | | - Francisco Morís
- EntreChem S. L., Edificio Científico Tecnológico, Campus El Cristo, Oviedo, Spain
| | - José A Salas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I. U. O. P.A), Universidad de Oviedo, Oviedo, Spain
| |
Collapse
|
48
|
Vizcaíno C, Rodríguez-Sánchez MA, Núñez LE, Morís F, Portugal J. Cytotoxic effects of mithramycin DIG-MSK can depend on the rise of autophagy. Toxicol In Vitro 2015; 29:1537-44. [PMID: 26079942 DOI: 10.1016/j.tiv.2015.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Revised: 06/11/2015] [Accepted: 06/12/2015] [Indexed: 11/29/2022]
Abstract
DIG-MSK (demycarosil-3D-β-D-digitoxosyl mithramycin SK; EC-8042), a novel analogue of mithramycin A, induced autophagy in HCT116 human colon carcinoma and, to a lesser extent, in A2780 human ovarian carcinoma cell lines, which was followed by apoptosis and/or necrotic cell death in a time-dependent way. The effects of DIG-MSK included changes in the expression of a set of genes involved in autophagy, the progression of cells through the different phases of cell cycle, and their halting at the checkpoints. Cells treated with the glucose analogue 2-DG (2-deoxy-D-glucose), which induces autophagy because it impairs cell metabolism, or co-treated with 2-DG plus DIG-MSK, also showed altered gene expression and autophagy. In A2780 cells, some genes involved in autophagy were down-regulated by the different treatments, yet the levels of the proteins they encode could be enough to ensure autophagic flux. In HCT116 cells, up-regulation of several pro-autophagic genes resulted in strong autophagic response. Acidic cell organelles and autophagic flux were more evident in HCT116 than in A2780 cells. DIG-MSK was still cytotoxic in cells that underwent autophagy induced by 2-DG. Therefore, we verified that autophagy resulting from a stress response did not protect cells against DIG-MSK, but, instead, autophagy promoted by either 2-DG or the novel mithralogue can enhance the antitumour activity, which depended on the cell type.
Collapse
Affiliation(s)
- Carolina Vizcaíno
- Instituto de Biología Molecular de Barcelona, CSIC, Parc Cientific de Barcelona, Barcelona, Spain
| | | | | | | | - José Portugal
- Instituto de Biología Molecular de Barcelona, CSIC, Parc Cientific de Barcelona, Barcelona, Spain.
| |
Collapse
|
49
|
Ocana A, Cuenca M, Serrano G, Montero J, Corrales V, Morís F, Nuñez L, Pandiella A. Phospho-Kinase Expression and Anti-Tumoral Activity of the Novel Multikinase Inhibitor Ec-70124 in Colon Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Fernández-Guizán A, Mansilla S, Barceló F, Vizcaíno C, Núñez LE, Morís F, González S, Portugal J. The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription. Chem Biol Interact 2014; 219:123-32. [PMID: 24907531 DOI: 10.1016/j.cbi.2014.05.019] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Revised: 04/25/2014] [Accepted: 05/27/2014] [Indexed: 12/14/2022]
Abstract
DIG-MSK (demycarosyl-3D-β-D-digitoxosyl-mithramycin SK) is a recently isolated compound of the mithramycin family of antitumor antibiotics, which includes mithramycin A (MTA) and mithramycin SK (MSK). Here, we present evidence that the binding of DIG-MSK to DNA shares the general features of other mithramycins such as the preference for C/G-rich tracts, but there are some differences in the strength of binding and the DNA sequence preferentially recognized by DIG-MSK. We aimed at gaining further insights into the DIG-MSK mechanism of action by direct comparison with the effects of the parental MTA. Similar to MTA, MSK and DIG-MSK accumulated rapidly in A2780, IGROV1 and OVCAR3 human ovarian cancer cell lines, and DIG-MSK was a potent inhibitor of both basal and induced expression of an Sp1-driven luciferase vector. This inhibitory activity was confirmed for the endogenous Sp1 gene and a set of Sp-responsive genes, and compared to that of MTA and MSK. Furthermore, DIG-MSK was stronger than MTA as inhibitor of Sp3-driven transcription and endogenous Sp3 gene expression. Differences in the effects of MTA, MSK and DIG-MSK on gene expression may have a large influence on their biological activities.
Collapse
Affiliation(s)
- Azahara Fernández-Guizán
- Departamento de Biología Funcional, Facultad de Medicina, Universidad de Oviedo, E-33006 Oviedo, Spain
| | - Sylvia Mansilla
- Instituto de Biología Molecular de Barcelona, CSIC, Parc Cientíific de Barcelona, E-08028 Barcelona, Spain
| | - Francisca Barceló
- Departament de Biologia Fundamental i Ciencies de la Salut, Universitat de les Illes Balears, E-07122 Palma de Mallorca, Spain
| | - Carolina Vizcaíno
- Instituto de Biología Molecular de Barcelona, CSIC, Parc Cientíific de Barcelona, E-08028 Barcelona, Spain
| | - Luz-Elena Núñez
- EntreChem SL, Edificio Científico Tecnológico, Campus El Cristo, E-33006 Oviedo, Spain
| | - Francisco Morís
- EntreChem SL, Edificio Científico Tecnológico, Campus El Cristo, E-33006 Oviedo, Spain
| | - Segundo González
- Departamento de Biología Funcional, Facultad de Medicina, Universidad de Oviedo, E-33006 Oviedo, Spain
| | - José Portugal
- Instituto de Biología Molecular de Barcelona, CSIC, Parc Cientíific de Barcelona, E-08028 Barcelona, Spain.
| |
Collapse
|